Uncategorized
Kala highlights investigational KPI-121
CHICAGO – At the Ophthalmology Innovation Summit here, Charles McDermott, interim president and CBO of Kala Pharmaceuticals, discusses KPI-121, the company’s mucosal penetrating nanoparticle formulation.